Stock Price, News, Quote and Profile of PSYENCE BIOMEDICAL LTD(NASDAQ:PBM) stock

PSYENCE BIOMEDICAL LTD

NASDAQ:PBM (12/20/2024, 8:00:02 PM)

After market: 2.3 -0.88 (-27.67%)

3.18

+0.72 (+29.27%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustryBiotechnology

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%-380.6%

Sales Q2Q%N/A

CRS0

6 Month-89.13%

Overview

Earnings (Last)08-12 2024-08-12

Earnings (Next)N/A N/A

Ins OwnersN/A

Inst Owners236.06%

Market Cap2.70M

Shares850.00K

PEN/A

Fwd PEN/A

Dividend YieldN/A

AnalystsN/A

Short Float %N/A

Short Ratio0

IPO12-10 2021-12-10

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Psyence Biomedical Ltd. is a life science biotechnology company. The company is headquartered in Toronto, Ontario. The company went IPO on 2021-12-10. The firm has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.

Company Info

PSYENCE BIOMEDICAL LTD

121 Richmond Street West Penthouse, Suite 1300

TORONTO ONTARIO V6E 3Z3

P: 17744604171

CEO: John Plourde

Employees: 0

Website: http://psyence.com

PBM News

7 hours ago - ChartmillThese stocks are moving in today's after hours session

After hours stock analysis on 2024-12-20: top gainers and losers in today's session.

16 hours ago - ChartmillWhich stocks are moving before the opening bell on Friday?

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.

a day ago - ChartmillTop movers in Thursday's session

What's going on in today's session

a day ago - ChartmillKeep an eye on the top gainers and losers in Thursday's session, as they reflect the most notable price movements.

Top movers analysis in the middle of the day on 2024-12-19: top gainers and losers in today's session.

4 days ago - Psyence Biomedical Ltd.Psyence Biomed Highlights Recent Progress on Active Phase IIb Clinical Trial

Patient screening underway; first patient expected to be randomized into the study in January A leading clinical trial site management organization (SMO),...

11 days ago - ChartmillGet insights into the top gainers and losers of Tuesday's pre-market session.

Top movers in Tuesday's pre-market session

PSYENCE BIOMEDICAL LTD (PBM)

Nasdaq Stock Screener

USA Stock Screener